Skip to main content

A pan-immune panorama of bacterial pneumonia revealed by a large-scale single-cell transcriptome atlas.

Signal transduction and targeted therapy2025-01-06PubMed
Total: 80.5Innovation: 9Impact: 8Rigor: 7Citation: 9

Summary

Using scRNA-seq of 444k BALF cells from 74 participants, the study maps immune circuits across disease severities in bacterial pneumonia. Severe disease is dominated by S100A8/A9 and CXCL8 programs from specific macrophage and neutrophil subsets, whereas mild disease shows Tfh/Th2 expansion supporting humoral responses; T-cell exhaustion occurs in both, but cytotoxic CD8+ T cells are better preserved in mild cases.

Key Findings

  • Severe bacterial pneumonia featured systemic upregulation of S100A8/A9 and CXCL8 from distinct macrophage and neutrophil subsets.
  • Mild disease showed expansion of Tfh and Th2 cells, promoting B-cell activation and antibody production.
  • T-cell exhaustion was present in both severities, with better preservation of cytotoxic CD8+ T cells in mild cases.
  • Findings were validated by ELISA and histology within the same cohort.

Clinical Implications

Severity stratification could incorporate S100A8/A9 and CXCL8 measurements; therapies dampening these pathways or boosting humoral responses may benefit selected subsets.

Why It Matters

Provides a reference single-cell atlas and actionable cytokine axes (S100A8/A9, CXCL8) linked to severity, enabling biomarker development and targeted immunomodulation trials.

Limitations

  • Observational, cross-sectional design limits causal inference
  • BALF sampling may not capture tissue-resident programs or systemic compartments

Future Directions

Prospective studies to test S100A8/A9 or CXCL8 pathway inhibitors and to evaluate biomarker-driven stratification for adjunctive immunomodulation in bacterial pneumonia.

Study Information

Study Type
Cohort
Research Domain
Pathophysiology
Evidence Level
III - Prospective/observational cohort with mechanistic profiling and internal validation
Study Design
OTHER